More FDA Oversight Of DTC Ads May Be Needed To Curtail Misleading Claims, Study Argues
Clearer US guidance on DTC TV advertising and stronger enforcement would help reduce misleading claims and encourage drug makers to include more qualitative benefit/risk information in ads, according to a new study from Yale University researchers published in the Journal of General Internal Medicine.
You may also be interested in...
Drugs like Victoza, Farxiga, Jardiance, Trulicity, and Invokana were called out for promoting weight loss and blood pressure reduction by Yale University researchers in a new study published in the Journal of General Internal Medicine.
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.
US agency is taking a stand against TV ads that present a drug’s serious risks as people are dancing to music or engaging in other compelling activities.